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Abstract 
Occlusion of the middle cerebral artery (MCAo) is among the most common causes of ischemic 
stroke in humans. Cerebral ischemia leads to brain lesions existing of an irreversibly injured core 
and an ischemic boundary zone, the penumbra, containing damaged but potentially salvageable 
tissue. Using a transient occlusion (30 min) of the middle cerebral artery (tMCAo) mouse model in 
this cross-institutional study we investigated the neurorestorative efficacy of a dietary approach 
(Fortasyn) comprising docosahexaenoic acid, eicosapentaenoic acid, uridine, choline, 
phospholipids, folic acid, vitamins B12, B6, C, and E, and selenium as therapeutic approach to 
counteract neuroinflammation and impairments of cerebral (structural+functional) connectivity, 
cerebral blood flow (CBF), and motor function. Male adult C57BL/6j mice were subjected to right 
tMCAo using the intraluminal filament model. Following tMCAo, animals were either maintained 
on Control diet or switched to the multicomponent Fortasyn diet. At several time points after 
tMCAo, behavioral tests, and MRI and PET scanning were conducted to identify the impact of the 
multicomponent diet on the elicited neuroinflammatory response, loss of cerebral connectivity, 
and the resulting impairment of motor function after experimental stroke. Mice on the 
multicomponent diet showed decreased neuroinflammation, improved functional and structural 
connectivity, beneficial effect on CBF, and also improved motor function after tMCAo. Our 
present data show that this specific dietary intervention may have beneficial effects on structural 
and functional recovery and therefore therapeutic potential after ischemic stroke. 
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Animal Model 
Introduction 
Stroke is the second leading cause of morbidity 
and mortality [1], and the most common cause of 
serious adult long-term disability in the United States 
[2, 3]. Ischemic strokes have been the target of many 
failed drug trials [4] and only few treatment options 
are available, but many patients still show significant 
poststroke disabilities [5-7]. Until now, thrombolysis 









ischemic stroke, but not many patients benefit from 
these therapies due to the narrow therapeutic window 
and complexity of administration [3, 8].  
There is therefore an urge for restorative 
interventions supporting better recovery and 
improving quality of life. Damaged brain networks 
have been shown to be responsible for absence of 
recovery or even for progressive disease, leading to 
increased mortality [9]. Furthermore, 87% of all 
strokes are ischemic [10], indicating that specific 
treatments should aim to improve impairments in 
cerebral blood flow (CBF) [4]. Therefore, stroke 
studies are needed investigating the effects of stroke 
and its interaction with a novel treatment on 
parameters being alternated after a stroke CBF, 
structural and functional connectivity, 
neuroinflammation, neuro- and synaptogenesis, 
vascular density, cognition, and behavioral 
parameters (motor coordination, activity etc.). Novel 
approaches targeting CBF, neuroinflammation, and 
brain networks may provide new avenues for stroke 
treatment [11]. In particular, dietary approaches could 
facilitate recovery after stroke [12, 13] because it has 
been shown that increased adherence to a 
Mediterranean-style diet is associated with a lowered 
risk of ischemic stroke and myocardial infarction [14]. 
Following MCA occlusion, mice fed a rapeseed 
oil-enriched diet revealed a decreased mortality rate, 
lowered levels of lipid peroxidation, and a reduced 
infarct size [15]. Also low fish consumption may 
already decrease the incidence of ischemic stroke [16]. 
In women, intake of omega-3 long-chain 
polyunsaturated fatty acids (n3-LCPUFA) is 
associated with a lowered risk of total stroke, while 
dietary cholesterol has been found to be positively 
associated with risk of total stroke and cerebral 
infarction [17]. In several other studies n3-LCPUFA 
have shown to diminish severity of vascular risk 
factors, like atherosclerosis [18], high blood pressure 
[19], and other cardiovascular diseases [18, 20-22]. 
Ozen et al. demonstrated a protective effect of 
n3-LCPUFA against cerebral ischemia in rats, 
showing a reduced number of apoptotic neurons in 
the prefrontal cortex when fed a standard diet 
combining eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) [23]. Moreover, 
combined administration of DHA and UMP 
improved learning abilities in rats [24] and combined 
administration of DHA and EPA improves (cerebral) 
vascular health in human [25, 26]. Supplementation of 
DHA and choline to normal adult gerbils also 
enhanced performance on several maze tests, being 
even further enhanced by coadministering UMP [27]. 
Additionally, in several studies a specific combination 
of nutrients called Fortasyn, comprising precursors 
and cofactors for membranes (DHA, EPA, uridine 
monophosphate (UMP), choline, phospholipids, folic 
acid, vitamins B12, B6, C, and E, and selenium), has 
been shown to support synergistically neuronal 
membrane synthesis [28, 29], increasing levels of brain 
phospholipids, dendritic spines and neurite 
outgrowth, cerebral blood flow, and to beneficially 
affect cognition [30-34]. Recently, we showed that this 
latter Fortasyn diet increased cortical CBF and 
synaptic density, and improved white matter integrity 
and functional connectivity (FC) in aging apoE4 
mouse. Furthermore, we demonstrated that protective 
mechanisms on vascular and synapse health are 
enhanced by Fortasyn, independent of apoE genotype 
[35]. In another AD murine model, we showed that 
this multi-nutrient supplementation diet improved 
cerebrovascular health and protected against 
neuronal degeneration [36]. This neurorestorative 
potential of Fortasyn has recently been obtained in a 
rodent model of spinal cord injury as well [37]. 
Thus, in present experiment we wanted to 
investigate the possible efficacy of this 
multicomponent diet as therapeutic intervention after 
transient ischemic stroke on both structural and 
functional parameters. Using state-of-the-art imaging 
techniques, we measured CBF, and the 
neuroinflammatory response after ischemia. Notably, 
upon activation during the neuroninflammatory 
response, microglial cells express the translocator 
protein (TSPO) [38, 39]. In vivo positron emission 
tomography (PET) for imaging of microglial 
activation has focused on a variety of radiolabeled 
compounds binding to TSPO. In particular, the 
second generation TSPO tracer 
N,N-diethyl-2-(2-(4-(2-[18F]fluoroethoxy)phenyl)-5,7-d
imethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide 
([18F]DPA-714) has been assessed for temporal and 
spatial evaluation of inflammatory alterations in 
models of cerebral ischemia, experimental 
autoimmune encephalomyelitis and cancer [40].  
Material and methods 
Animals and diets (Nijmegen, The 
Netherlands; Münster, Germany) 
In total 48 3–4 months old C57BL/6J mice 
(Nijmegen, 24 mice: Harlan Laboratories Inc., Horst, 
the Netherlands; Münster, 24 mice 3–4 months old 
in-house bred C57BL/6J mice) were used for this 
cross-institutional, randomized, and double-blind 
controlled study (blinded for investigators and 
outcomes assessor) conducted at the preclinical 
imaging center (PRIME) of the Radboudumc 
(Nijmegen, the Netherlands) and the European 
Institute for Molecular Imaging (EIMI, Münster, 





Germany). Before tMCAo, the animals were housed 
socially with a maximum of six animals per cage, with 
room temperature at 21°C, and artificial 12:12h light: 
dark cycle (lights on at 7 a.m.). After stroke induction, 
the mice were housed separately to control the food 
intake of the experimental diets (see below). Food and 
water were available ad libitum. Samples sizes were 
determined by power analysis during the animal 
ethics dossier application. The experiments 
(Nijmegen) were performed according to Dutch 
federal regulations for animal protection and were 
approved by the Veterinary Authority of the Radboud 
university medical center, Nijmegen, The 
Netherlands. Experiments (Germany) were in 
accordance with the German Law on the Care and 
Use of Laboratory Animals and approved by the 
Landesamt für Natur, Umwelt und 
Verbraucherschutz of North Rhine-Westphalia. All 
experiments (Nijmegen & Münster) of this 
international multicenter preclinical study were 
exerted in accordance to the ARRIVE [41] and the 
(updated) STAIR guidelines [42-44]. All applicable 
international, national, and institutional guidelines for 
the care and use of animals were followed. 
Before tMCAo all mice were fed a standard 
Control diet (Ssniff rm/h V1534-000, Bio Services, 
Uden, The Netherlands). Starting right after tMCAo, 
mice were randomly divided in two groups; animals 
were fed either Control or Fortasyn diet that differed 
with respect to their fatty acid composition and some 
additional nutrients. All diets were isocaloric and 
based on AIN-93M (Reeves et al., 1993) with 5% fat. 
The Control diet contained 1.9% soy oil, 0.9% coconut 
oil and 2.2% corn oil. The Fortasyn diet contained 
0.1% coconut oil, 1.9% corn oil and 3.0% fish oil. The 
Fortasyn diet contains a specific multi-nutrient 
composition comprising uridine, omega-3 PUFAs, 
choline, B vitamins, phospholipids and antioxidants 
as specified in Table 1. To assure 
intercenter-comparability and accordance to the 
ARRIVE and (updated) STAIR guidelines in this 
study, all experiments were performed in line with 
the following predefined experimental rules. In this 
experiment we used a study design with pre-set 
endpoints for all participating centers (Münster & 
Nijmegen). Both diets were manufactured and 
pelleted by Ssniff (Soest, Germany) and stored at 
−20°C until use. All mice underwent behavioral tests 
before and after tMCAo. 35 days poststroke, MRI 
measurements were performed and all animals were 
euthanized after completion of the study. Post 
mortem immunohistochemical procedures were 
performed on all brains. The time line of the 
experimental design is illustrated in figure 1. No 
potential disparities in verum/ control group 
allocation are given. The random allocation of each 
mouse into its test group was performed by a blinded 
researcher. To insure intercenter-comparability, all 
surgeries were performed by the same experienced 
researcher (D. R.) in Münster, Germany, and in 
Nijmegen, the Netherlands. For all surgeries, the same 
type of filaments (70SPRePK5, Doccol Corp., Sharon, 
MA, USA) for the occlusion of the MCA was used in 
Münster, Germany, and in Nijmegen, the Netherlands 
and the same batch of diets were tested in both 
centers. Furthermore, in Nijmegen, the Netherlands, 
all imaging and behavioral procedures were 
performed by the same researchers. In accordance, in 
Münster, Germany, all imaging procedures were 
performed by the same investigator. Moreover, all 
analyses of behavioral, imaging, and 
immunohistochemical data were performed by 
blinded researchers. 
 
Table 1. Oil sources and additives in the isocaloric experimental 
diets. 
5% Fat  Diets 
Control [g/100 g]  Fortasyn [g/100 g] 
Oils 
Soy oil 1.9  - 
Coconut oil 0.9  0.1 
Corn oil 2.2  1.9 
Fish oil -  3.0 
Additives 
Pyridoxine-HLC -  0.00328 
Folic acid (90%) -  0.00067 
Cyanocobalamin -  0.00350 
Ascorbic acid -  0.160 
Dl-α-tocopheryl acetate -  0.465 
Uridine monophosphate (UMP) -  1.0 
Choline chloride (74.6%) -  0.402 
Sodium selenite (46%) -  0.00023 
Soy lecithin (Emulpur) -  0.755 
 
 
Transient Middle Cerebral Artery Occlusion 
Surgery (Nijmegen, The Netherlands; 
Münster, Germany) 
3 months old, male C57BL/6J mice underwent 
right tMCAo (30 minutes), using an intraluminal 
occlusion model as described elsewhere with minor 
modifications [45, 46]. This stroke model of transient 
occlusion of the MCA mimics one of the most 
common types of ischemic stroke in patients [45, 47]. 
The MCA was transiently occluded for 30 min. This 
ischemia time leads to moderate pathological changes 
within the infarct core, perilesional and remote 
regions [48-50]. In accordance with human stroke this 
reperfusion model involves a substantial degree of 
reperfusion via collateralization through the circle of 
Willis and leptomeningeal collaterals, and via early 
clot lysis [51]. In summary, mice were anesthetized 





with 1.5% isoflurane (Abbott Animal Health, Abbott 
Park, IL, USA) in a 2:1 air and oxygen mixture. After 
preparing the right common carotid artery, a 7-0 
monofilament (tip diameter 190 to 200 μm, coating 
length 2 to 3 mm, 70SPRePK5, Doccol Corp., Sharon, 
MA, USA), was inserted in the common carotid artery 
and positioned at the point where the MCA branches 
out. Successful occlusion was maintained for 30 
minutes before retracting the filament allowing 
reperfusion. Reduction in blood flow was monitored 
intraoperatively via a Laser Doppler probe 
(Nijmegen, moorVMS-LDF2, Moor Instruments, UK; 
Münster, Periflux 5000, Perimed Instruments, Järfälla, 
Sweden) attached to the skull of the mouse. Using the 
Laser Doppler Flow measurement, we considered an 
induction of ischemia as valid, when during the 
occlusion a decrease in regional CBF of more than 
80% of baseline values at filament insertion is reached 
(inclusion criterion). Mice were kept under 1.5% 
isoflurane anesthesia in a 2:1 air and oxygen mixture 
throughout the procedure. Body temperature was 
maintained at physiological levels with a custom built 
heating pad. Exclusion criteria were: a decreased 
motor activity (<50% of the baseline measurements 
combined from the baseline values of each behavioral 
test) or extreme weight loss (>20% within three 
consecutive days). Using a T2-weighted RARE 
sequence to measure lesion size, all animals showed a 
comparable lesion size and no dietary effect on lesion 
size (data not shown). In all animals N=3 Control 
animals and n=4 animal on Fortasyn diet died during 
first week poststroke in Nijmegen, the Netherlands. 
N=2 Control animals and n=1 animal on Fortasyn diet 
died during the experiments in Münster, Germany. 
Behavioral and cognitive tests (Nijmegen, The 
Netherlands) 
Open field 
Locomotion and explorative behavior were 
evaluated for 10 minutes in the open field prior to the 
tMCAo, and also 3 and 23 days poststroke as 
previously described [52-55]. Using EthoVision 
XT10.1 (Noldus, Wageningen, The Netherlands), 
locomotion was automatically recorded. The floor of 
the arena was divided into center, periphery, and 
corners. The frequency of entering these zones was 
measured automatically. In addition, exploration was 
manually scored (walking, sitting, wall leaning, 
jumping, rearing, grooming) and analyzed as 
described previously [56, 57]. 
Grip strength test 
Grip strength test was performed at 14 days 
poststroke using a grip strength meter (Grip-Strength 
Meter, 47200, Ugo Basile, Italy) to determine forelimb 
and also total limb (fore- and hindlimbs combined) 
muscle strength. Each mouse was trained prior to 
tMCAo to perform this test. The grip strength meter 
was arranged horizontally on the table. While holding 
the tails, the mice were lowered towards the grip 
strength meter to enable to grasp the grip trapeze with 
the forepaws or the grid with both their fore- and 
hindpaws. After grasping the trapeze or the grid, the 
mice were pulled backwards till the grasp was 
released. The test was repeated five consecutive times 
first with the trapeze and one hour later with the 
grasping grid. For each session the average value of 
the peak force (in gf) was calculated from the last 
three trials [58] and the first two trials were used as 
acclimatization. Additionally, trials were only 
analyzed, in which the mouse grasped with either two 
forepaws (trapeze) or all four paws (grid). 
Pole test 
The pole test was performed at day 15 
poststroke, as previously described [59]. The mice 
were placed head upward just below the top of a 
vertical rough-surfaced pole (diameter 2.5 cm; height 
60 cm) and then allowed to descend. This procedure 
was repeated five times. Each mouse was trained 
prior to tMCAo to perform this behavioral test. The 
time taken to turn completely downward and the 
rotation direction were measured manually, while the 
time to reach the floor was determined in EthoVision 
XT10.1 (Noldus, Wageningen, The Netherlands) to 
measure downward velocity (cm/s). Laterality index 
is determined by the averaged turn direction of each 
mouse (0= left/ contralateral turn, 1= right/ 
ipsilateral turn). A laterality index of 0.5 indicates that 
no lateralization is present, while a laterality index of 
0.0 respectively 1.0 suggests a laterality of more 
contralateral respectively ipsilateral turns. Results for 
downward velocity and rotation time are displayed as 
the mean of minimal three successful trials. The first 
acquisition trial was excluded from the statistical 
analysis and used as acclimatization trial. 
MRI protocol (Nijmegen, The Netherlands) 
MRI measurements were performed at 7 and 35 
days poststroke on a 11.7 T BioSpec Avance III small 
animal MR system (Bruker BioSpin, Ettlingen, 
Germany) equipped with an actively shielded 
gradient set of 600 mT/m and operating on 
Paravision 5.1 software platform (Bruker, Karlsruhe, 
Germany). We used a circular polarized volume 
resonator for signal transmission and an actively 
decoupled mouse brain quadrature surface coil with 
integrated combiner and preamplifier for receiving 
(Bruker BioSpin). For the imaging procedure, the 
animals were anesthetized with isoflurane (3.5% for 





induction and 1.8% for maintenance) in a 2:1 oxygen 
and N2O mixture, and placed in a stereotactic holder 
to prevent unwanted movement during the scanning. 
Body temperature was monitored with a rectal probe 
and maintained at 37˚C with heated airflow. 
Respiration of the animal was monitored using a 
pneumatic cushion respiratory monitoring system 
(Small Animal Instruments Inc, NY, USA). First 
gradient echo images were acquired using previously 
described image parameters [36].  
Cerebral blood flow 
MR perfusion data were acquired under resting 
conditions using established methods with a 
flow-sensitive alternating inversion recovery (FAIR) 
technique [60, 61]. 
Regional perfusion was evaluated in the cerebral 
cortex (all cortical regions above corpus callosum), 
hippocampus, thalamus [36] accordingly to the atlas 
of Franklin and Paxinos [62]. To calculate regional 
CBF we used the same protocol as previously 
described [36].  
Diffusion tensor imaging 
Diffusion of water was imaged as described 
previously [63, 64]. In short, 22 axial slices covering 
the whole brain were acquired with a four-shot 
SE-EPI protocol. B0 shift compensation, navigator 
echoes and an automatic correction algorithm to limit 
the occurrence of ghosts and artefacts were 
implemented. Encoding b-factors of 0 s/mm2 (b0 
images; 5×) and 1000 s/mm2 were used and 
diffusion-sensitizing gradients were applied along 30 
non-collinear directions in three-dimensional space.  
The diffusion tensor was estimated for every 
voxel using the PATCH algorithm [65]; mean water 
diffusivity (MD) and fractional anisotropy (FA) were 
derived from the tensor estimation following a 
protocol as described elsewhere [64]. MD and FA 
values were measured in several white matter (WM) 
and grey matter (GM) areas, manually selected based 
on an anatomical atlas [62], as described previously in 
[35]. 
Resting state fMRI 
The resting state fMRI (rsfMRI) datasets were 
first realigned using a least-squares method and 
rigid-body transformation with Statistical Parametric 
Mapping (SPM) mouse toolbox (SPM5, University 
College London; http://www.fil.ion.ucl.ac.uk/spm/; 
[66]). Mean and maximum displacement across the six 
degrees of freedom (along the x-, y-, and z-axes and 
on three rotation parameters pitch, roll, and yaw) 
were measured in each mouse. The mean SE-EPI 
images of each mouse were then used to generate a 
study-specific template through linear affine and 
nonlinear diffeomorphic transformation (ANTs. v1.9; 
http://picsl.upenn.edu/ANTS/). Visual inspection of 
the normalized dataset was performed to screen for 
possible normalization biases. On the template, 14 
areas were selected in left and right hemisphere. The 
selected regions were based on previous work in 
functional connectivity in mice [67], and includes: left 
and right dorsal hippocampus, left and right ventral 
hippocampus, left and right auditory cortex, left and 
right motor cortex, left and right somatosensory 
cortex, and left and right visual cortex. All cortical 
ROI were selected 1–2 voxels away from the edge of 
the cortex, to minimize the impact of 
susceptibility-weighted artefacts, which are more 
prominent in areas of different tissues interface (e.g., 
near the skull or near the ear canals). After motion 
regression, in-plane spatial smoothing (0.4 × 0.4 mm), 
linear detrending, and temporal high-pass filtering 
(cut-off at 0.01 Hz) were applied to compensate for 
small across-mouse misregistration and temporal 
low-frequency noise. FC group comparisons between 
ROI were calculated from the BOLD time series using 
total correlation and partial correlation analyses 
implemented in FSLNets (FSLNets v0.3; 
www.fmrib.ox.ac.uk/fsl). Pearson's correlation values 
were Fisher transformed to Z-scores for group 
comparisons and statistical analysis. 
[18F]DPA-714 Positron Emission Tomography 
(PET, Münster) 
During image acquisition, mice were 
anesthetized with 1.5% isoflurane (Abbott Animal 
Health) in pure oxygen. For tracer application, the 
lateral tail vein was cannulated using a 26 Ga catheter 
(Vasculon Plus, BD, Heidelberg, Germany) connected 
to a 15-cm polyethylene tubing (27 Ga, Smith Medical, 
Kent, UK).  
[18F]DPA-714 was prepared following the 
procedure described previously with a radioactive 
purity of 99% and a decay corrected yield (rcy) of 25.1 
± 4.9% [68]. 
Mice were injected with 15.7 ± 1.5 MBq of 
[18F]DPA-714 and imaged consecutively 7 
(n=5/group), 14 (n=8/group), and 35 (n=8/group) 
days poststroke. Only animals with complete imaging 
set (n=5 group) could be taken into consideration for 
repeated measurement ANOVA analysis. N=2 
animals per group without measureable infarction 
and DPA-714 PET changes were excluded from the 
analysis. PET data were acquired 45-55 min p.i. on a 
high-resolution small animal PET scanner (32 module 
quadHIDAC, Oxford Positron Systems Ltd., Oxford, 
UK) with uniform spatial resolution (1 mm FWHM 
(full-width at halfmaximum)) over a large cylindrical 
field-of-view (165 mm diameter, 280 mm axial length). 





Images were reconstructed with a one-pass list mode 
expectation maximization algorithm with resolution 
recovery. CT images were acquired on a small animal 
CT scanner (Inveon, Siemens Medical Solutions, 
Knoxville, TN, USA) with a spatial resolution of 80 
μm. For data analysis, CT images were coregistered to 
PET, followed by co-registration to MRI data using a 
landmark-based approach as described previously 
[46]. Magnetic Resonance Imaging studies were 
performed with a 9.4-T small animal MR scanner with 
20 cm bore size (Bios-Spec 94/20; BrukerBioSpin MRI 
GmbH, Ettlingen, Germany). The system was 
operated using the software ParaVision 5.1. 
(BrukerBioSpin MRI GmbH). Anatomic T2w RARE 
brain images were obtained in three imaging planes 
(28 planes, slice thickness 0.5 mm, in-plane resolution 
78 μm (repetition time 3,000 to 5,500 ms, echo time 50 
ms, rare factor 16, 6 averages, 14 to 28 contiguous 
slices, slice thickness 0.5 mm, field of view 20 mm2, 
256 matrix, in-plane resolution 78 μm2, scan time 5 to 
9 minutes, respectively). Image analysis was 
conducted with the VINCI software (Version: 4.19.0; 
http://www.nf.mpg.de/vinci3/) [69] by drawing a 
volume of interest (VOI) over the infarcted area 
depicted by T2w MRI. A duplicate VOI was mirrored 
to the contralateral hemisphere and served as control. 
Mean and maximum lesion-to-background 
(Lmean/Bmean and Lmax/Bmean) ratios were 
calculated. 
Immunohistochemical procedures (Nijmegen, 
The Netherlands; Münster, Germany) 
After the last scanning session, the mice were 
sacrificed by transcardial perfusion using 0.1M 
phosphate-buffered saline (PBS) followed by 4% 
paraformaldehyde in 0.1M PBS. The brains were 
harvested and stored separately. The brains were 
postfixed overnight in 4% paraformaldehyde at 4°C 
and transferred to 0.1M PBS containing 0.01% sodium 
azide the next day. One part of the brain (Bregma: -0.7 
to -4.36) was cut in 30 μm frontal sections using a 
sliding microtome (Microm HC 440, Walldorf, 
Germany) equipped with an object table for 
freeze-sectioning at -60°C. 24 Hours before cutting, 
the brains were transferred in 30% sucrose in 0.1M 
phosphate buffer. 8 Series were cut and stored in 0.1M 
PBS with 0.01% sodium azide so multiple 
immunohistochemical stainings could be performed. 
All sections were stained in one session to 
minimize differences in staining intensity. 
In total three stainings were performed for 
vascular integrity measured via glucose transporter-1 
(GLUT-1), for activated microglia via ionized 
calcium-binding adapter molecule 1 (IBA-1) as 
indicator for neuroinflammation, and for immature 
neurons (measure for neurogenesis) with antibodies 
against doublecortin (DCX) on free-floating brain 
sections on shaker tables at room temperature. 
Immunohistochemistry was performed using 
standard free-floating labelling procedures, using 
previously described protocols [70]. 
The GLUT-1 amount was visualized using 
polyclonal rabbit anti-GLUT-1 antibody 
(1:40.000,Chemicon AB 1340, Chemicon International, 
Inc., Temecula, CA, USA) and as secondary antibody 
donkey anti-rabbit biotin (1:1500 Jackson 
ImmunoResearch, West Grove,PA, USA). 
For IBA-1, as primary antibody against IBA-1 
polyclonal goat anti-IBA-1 (1:3000; Abcam) and for 
DCX, polyclonal goat anti-DCX (1:8000; Santa Cruz 
Biotechnology Inc., Santa 
Cruz, CA, USA) was used as a primary antibody 
to assess neurogenesis. For both as secondary 
antibody donkey anti-goat biotin (1:1500; Jackson 
ImmunoResearch, West Grove, PA, USA) was used. 
From a more frontal part of the brain tissue 
(Bregma: -0.10 to 0.98) was fixed in 4% 
paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) 
and embedded in paraffin according to a standard 
protocol. 
Synaptophysin (SYN; measure for synaptic 
plasticity) immuno reactive presynaptic boutons with 
antibodies against synaptophysin and postsynaptic 
density (measure for synaptic plasticity) with 
antibodies against postsynaptic density protein 95 
(PSD-95) was demonstrated immunohistochemically 
on 5 μm thin paraffin sections. 
We used monoclonal rabbit anti-synaptophysin 
clone EP1098Y (1:500; Abcam Inc., Cambridge, UK) as 
a primary antibody to visualize synaptophysin in 
presynaptic boutons. For PSD-95, polyclonal rabbit 
anti-PSD95 (1:800; Abcam Inc.) was used as a primary 
antibody to reveal the postsynaptic density. After 
washing 3 times with 0.1M PBS, for both the 
synaptophysin and PSD-95 staining, the secondary 
antibody used was donkey anti-rabbit biotin (1:200; 
Jackson ImmunoResearch), followed again by 3 
washes, Vector ABC-Elite (1:50) and the above 
mentioned DAB-Ni incubation 
Immunohistochemistry for TSPO (1:250, 
NBP1-95674, Novus Biologicals, Cambridge, UK) and 
GFAP (1:1000; Abcam Inc., Cambridge, UK) was 
performed on paraffin embedded slices. The slides 
were boiled in citrate buffer for antigen retrieval (pH 
6; 30 minutes), before being treated with blocking 
solution for 30 minutes (1%BSA and 0.5% Triton-X in 
PBS), Primary antibodies were subsequently 
incubated with the primary antibodies (4°C, 
overnight). TSPO immunoreactivity was visualized 
through a multi-step process, including incubation 





with a biotinylated goat anti-rabbit (1:800, 45 minutes, 
B21078, Life Technologies, Darmstadt, Germany), 
followed by HRP-Streptavidin incubation (20 
minutes, K1016, DAKO, Hamburg, Germany) and 
3,3-Diaminobenzidine (D-5637, 5 min, Sigma, 
Hamburg, Germany). Sections were counterstained 
with hematoxylin, dehydrated, cleared with xylol and 
mounted using Entellan (Merck, Darmstadt, 
Germany). For double immunohistochemistry slides 
were incubated with Alexa Fluor 488-conjugated 
anti-rabbit secondary antibody (1:800, A-21206, Life 
Technologies, Carlsbad, CA, USA), or Alexa Fluor 555 
conjugated anti-goat (1:800, A-21432, Life 
Technologies, Carlsbad, CA, USA). Slides were 
mounted in DAPI containing mounting medium 
(Vectashield, H-1500, Vector Laboratories, 
Burlingame, CA, USA). Images were acquired with a 
combined fluorescence-light microscope (Nikon 
Eclipse NI-E, Nikon, Tokyo, Japan). 
Quantification (SYN and PSD-95) 
The stained sections (Bregma: 0.02 to 0.62) were 
analyzed using a Zeiss Axioskop microscope 
equipped with hardware and software of 
Microbrightfield. Brain regions were based on the 
mouse brain atlas of Paxinos and Franklin [62] and 
quantified in four regions of the hippocampus: left 
cortex, right cortex, left caudate putamen, and right 
caudate putamen. The relevant regions were digitized 
with a 40x objective and using Stereo Investigator 
software for finding the right location for the image. 
The quantification of the images was performed using 
ImageJ (National Institute of Health, Bethesda, MD, 
USA). 
Quantification (GLUT-1, IBA-1 and DCX) 
Brain sections (Bregma: -1.46 to -2.30) were 
preselected for quantification accordingly to the atlas 
of Franklin and Paxinos [62]. Quantification was done 
on images at a 5x objective using an Axio Imager A2 
(Zeiss Germany). ImageJ (National Institute of Health, 
Bethesda, MD, USA) was used to analyze the regions 
of interest (GLUT-1+IBA-1: Cortex, hippocampus and 
thalamus; DCX: Hippocampus, and the 
subventricular zone, called SVZ).  
Statistics 
For the statistical analysis, IBM SPSS 22 software 
(IBM Corporation, New York, NY, USA) was used. 
Multivariate ANOVA or univariate ANOVA both 
with Bonferroni corrections (using Repeated 
measures ANOVA, when necessary, for example 
open field and PET data) was conducted with 
between-group-factor diet and if necessary also time 
to analyze possible differences in all the other 
parameters. 
Statistical significance was set at p ≤ 0.05: #, 0.05 
< p < 0.08 (tendency); *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 
0.001. Degrees of freedoms, f-values and p-values are 
given for each statistical analysis. All data are 
expressed as mean ± SD. #, 0.05 < p < 0.08 (tendency); 
*, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001. 
Results  
A summary of all experimental results is given in 
table 2. 
Food intake and body weight (Nijmegen, The 
Netherlands) 
Body weight of both dietary groups decreased 
poststroke, while it increased significantly over time, 
comparing the first with the second to fifth week 
poststroke in all mice, for further details see 
supplemental material and supplemental figure 1A.  
The daily food intake increased over time on 
both diets in all mice. Fortasyn diet tended to increase 
food intake compared to Control diet, for further 
details see supplemental material and supplemental 
figure 1B. 
Behavioral and cognitive tests (Nijmegen, The 
Netherlands) 
Open field 
Open field was performed for 10 minutes to 
measure locomotion (total walking distance, velocity), 
frequency of zone enters (corners, center, periphery), 
exploration frequency (walking, wall leaning, rearing, 
sitting) and grooming, prior to tMCAo (baseline), 3 
and 23 days after tMCAo. 
Both diet groups exhibited a decreased total 
distance walked (Figure 2A; F(1,12)=87.8, p<.001) and 
velocity (Figure 2B; F(1,12)=84.2, p<.001) three days 
poststroke compared to baseline. 
The frequency of entering the three zones of the 
open field (Figure 2C), corners (F(1,12)=61.5, p<.001), 
periphery (F(1,12)=55.9, p<.001), and center 
(F(1,12)=35.3, p<.001) were also decreased in both diet 
groups comparing before and three days poststroke. 
From three to 23 days poststroke, both diet groups 
increased their frequency of entering the center 
(F(1,13)=81.9, p<.001) and periphery (F(1,13)=4.1, 
p<.065) again. 
Measured via manual scoring (Figure 2D), 
frequencies of walking (F(1,12)=39.4, p<.001), wall 
leaning (F(1,12)=28.2, p<.001), and rearing 
(F(1,12)=17.4, p<.002) were decreased, and frequency 
of grooming (F(1,12)=3.7, p<.079) was increased in 
both diet groups comparing before with three days 
after tMCAo. In contrast, from 3 to 23 days poststroke, 
mice showed an increase in frequency of sitting 
(F(1,13)=5.1, p<.042), and decrease in frequency of 





grooming (F(1,13)=11.1, p<.006).  
Notably, a diet effect was shown over time on 
frequency of walking (F(1,13)=8.1, p<.014). Only mice 
on Fortasyn diet walked more often overtime 
(F(1,13)=10.2, p<.019). 23 days poststroke, Fortasyn 
fed mice walked more frequently than Control fed 
mice (F(1,13)=4.6, p<.052, trend). 
Grip strength test 
The grip strength test was performed to quantify 
muscle strength (of forepaws respectively of fore- 
hindlimbs combined) at 14 days poststroke. 
 
Table 2. Summary of all significant results. Used abbreviations: CBF (cerebral blood flow), DTI (diffusion tensor imaging), FA (fractional 
anisotropy), MD (mean diffusivity), rsfMRI (resting state functional MRI), Total (total correlations), Partial (partial correlations), IHC 
(Immunohistochemistry), GLUT-1 (glucose transporter-1), IBA-1 (ionized calcium-binding adapter molecule 1), DCX (doublecortin), SYN 
(synaptophysin), PSD-95 (postsynaptic density protein 95). 
Parameter Results 
Body weight ↓ in both groups at 7D; ↑ in both groups at 35D  
Food intake ↑ in both groups at 35D; (↑) at 7D+35D in Fortasyn mice 
Open field Distance ↓ in both groups at 3D 
Velocity ↓ in both groups at 3D 
Frequency of entering: Corners ↓ in both groups at 3D 
Periphery ↓ in both groups at 3D; ↑ in both groups at 23D 
Center ↓ in both groups at 3D; (↑) in both groups at 23D 
Manual scoring 
(frequency): 
Walking ↓ in both groups at 3D; ↑ at 23D in Fortasyn mice 
Leaning ↓ in both groups at 3D 
Rearing ↓ in both groups at 3D 
Grooming (↑) in both groups at 3D 
Stitting ↑ in both groups at 23D 
Grip strength test Grid (All limbs) (↑) in Fortasyn mice 
Pole test Rotation Time ↓ in Fortasyn mice 
Rotation direction (No laterality present in Fortasyn mice) 
FAIR-ASL Cortex CBF ↓ in right cortex of both groups at 7D; ↑ in right cortex of Fortasyn mice 
than control mice at 7D; ↓ in right cortex of control mice at 35D; ↓ in left 
cortex of control mice over time 
Loss ↓ in Fortasyn mice than in control mice at 7D; ↓ over time in both groups 
Hippocampus CBF ↓ in right hippocampus of both groups at 7D; ↓ in right hippocampus of 
control mice at 35D; ↑ in right hippocampus of Fortasyn mice than 
control mice at 35D; (↓) in left hippocampus of control mice over time; ↑ 
in right hippoampus of Fortasyn mice over time 
Loss ↓ in both groups over time; ↓ in Fortasyn mice than in control mice at 
35D 
Thalamus CBF ↓ in right thalamus of both groups at 7D; ↓ in right thalamus of both 
groups at 35D; ↑ in left thalamus of Fortasyn mice than control mice at 
35D; ↑ in right thalamus of Fortasyn mice over time 
Loss ↓ in Fortasyn mice over time 
DTI FA Corpus callosum (↑) in left corpus callosum of both groups over time 
Hippocampus ↑ in left+right hippocampus of both groups over time 
Motor cortex (↑) in right motor cortex of Fortasyn mice at 7D+35D 
Optic tract (↑) in left corpus callosum of both groups over time 
Visual cortex ↓ in right visual cortex of control mice at 35D 
Cpu+GP ↓ in right Cpu+GP at 7D; ↑ in right Cpu+GP of Fortasyn mice over time 
MD Fornix (↓) in both groups over time  
Motor cortex (↓) in right motor cortex of Fortasyn mice at 7D+35D 
Cpu+GP (↓) in left Cpu+GP of control mice over time; ↑ in right Cpu+GP of 
control mice at 35D 
rsfMRI Partial Overall ↓ in Fortasyn mice at 7D + ↑ in Fortasyn mice at 35D; less negative 
effects over time in Fortasyn mice; ↑ in motor cortex of Fortasyn mice at 
35D 
PET DPA-714 in infarct ↓ in Fortasyn mice  
IHC GLUT-1 +cells Cortex ↑ in Fortasyn mice; ↑ in right cortex of Fortasyn mice 
IBA-1 +area Cortex (↓) in Fortasyn mice 
Hippocampus (↓) in Fortasyn mice 
Thalamus ↑ in right thalamus; (↑) in Fortasyn mice 
+cells Hippocampus ↓ in Fortasyn mice; ↓ in right hippocampus of Fortasyn mice 
Thalamus ↑ in right thalamus 
DCX +area SVZ ↑ in right SVZ of Fortasyn mice 
SYN +area Cpu ↓ in right Cpu 
PSD-95 +area Cortex ↓ in right cortex 
Cpu ↓ in right Cpu 
TSPO   ↓ in Fortasyn mice 
 






Fig. 1. Study design. Behavioral and MRI studies were performed in Nijmegen, the Netherlands. After a transient occlusion of the middle cerebral artery (tMCAo) 
for 30 min, mice were divided into two dietary groups (Control or Fortasyn). At 7 and 14 days post tMCAo all mice underwent MRI. In between, all mice were tested 
on motor and cognitive impairments via several behavioral tests, like the Open field, Rotarod, Pole test, Prepulse inhibition (Ppi), grip strength test, and novel object 
recognition test (ORT). After MRI, all brains were processed for immunohistochemical stainings. PET imaging studies were conducted in parallel in Münster, 
Germany. [18F]DPA-714 PET was conducted 7, 14 and 35 d after tMCAo in two dietary groups (Control or Fortasyn). T2w MRI for anatomical localization of stroke 
was conducted 14 d post tMCAo. The group sizes at the start and at the end of the experiments performed in Nijmegen, the Netherlands, and in Münster, Germany, 
are given. The group sizes shown in brackets indicates the number of mice used for the behavioral or imaging procedures and quantification. The dashed line indicates 
the period of time of exclusion of mice due to i.e. surgical problems, humane endpoint. 
 
 
Fig. 2 Effects of Fortasyn on locomotion (A+B), time spent in different zones (C), and exploration in open field measured prior to tMCAo (PO), 
and 3 and 23 days poststroke (E) grip strength test 14 days poststroke g-f; gram-force (F-H) motor coordination determined via pole test 15 
days poststroke. Values represent mean±SD. (A+B) Both diets exhibited decreased total distance walked (p<.001) and velocity (p<.001) comparing before, and 
three days poststroke. (C) Frequency of entering corners (p<.001), periphery (p<.001), and the center (p<.001) were decreased in both diet groups comparing 
before, with three days poststroke. From three to 23 days after tMCAo, both diet groups increased frequency of entering center (p<.001) and periphery (p<.065). 
(D) Frequencies of walking (p<.001), wall leaning (p<.001), and rearing (p<.002) were decreased. All mice showed increased frequency of sitting (p<.042), and 
decreased frequency of grooming (p<.006) poststroke. Mice on Fortasyn walked more at 23 days compared to 3 days poststroke (p<.019). At 23 days poststroke, 
Fortasyn fed mice tended to walk more frequently than Control fed mice (p<.052). (E) No diet effect was found in muscle strength of the forepaws (trapeze). 
Measuring total limb strength (grasping grid), revealed higher muscle strength on Fortasyn tended (p<.057). (F) No diet effects were observed concerning velocity to 
descend along the pole. (G) Control fed mice needed a longer turning time than Fortasyn fed mice when placed head-upwards on top of the pole (p<.010). (H) Mice 
fed Control diet displayed an ipsilateral bias to fully turn head-down (p<.058, trend). 






Fig. 3. Cerebral blood flow (CBF) determined with flow-sensitive alternating inversion recovery (FAIR) MRI 7 and 35 days after tMCAo in 
cortex, hippocampus and thalamus of mice on Fortasyn or Control diet. Values represent mean±SD. (B) Representative high-resolution voxel-wise 
analyzed CBF image at 7 and 35 poststroke. (A) 7 days poststroke CBF in right cortex (Control, p<.001; Fortasyn, p<.001), right hippocampus (Control, p<.001; 
Fortasyn, p<.001), and in right thalamus (Control, p<.005; Fortasyn, p<.001) were lower than corresponding left ROI for both diets. Mice on Fortasyn showed 
increased CBF in right affected cortex (p<.017). 35 days poststroke, Control mice demonstrated lower CBF in right cortex (p<.043), right hippocampus (p<.010), and 
right thalamus (p<.015) compared to left ROI, while Fortasyn mice demonstrated decreased right thalamic CBF (p<.002) and a higher CBF than control mice in left 
cortex (p<.040), right hippocampus (p<.045), and also left thalamus (p<.020) at day 35. Control mice showed a decreased left cortical (p<.002) and left hippocampal 
(p<.079) CBF over time, Fortasyn fed animals showed increased CBF in right hippocampus (p<.019) and right thalamus (p<.032) over time. (C) Fortasyn mice 
exhibited a less diminished cortical CBF at 7 days poststroke (p<.017) and in hippocampal CBF at 35 days poststroke (p<.040). CBF recovery was shown in cortex 
(Control, p<.007; Fortasyn, p<.040) and hippocampus (Control, p<.024; Fortasyn, p<.009), and thalamus (Fortasyn, p<.018). 
 
No diet effects in muscle strength of the 
forepaws was found (Figure 2E). The grasping grid 
revealed that mice on Fortasyn diet tended to have 
higher muscle strength than mice on Control diet 
(F(1,13)=4.5, p<.057). 
Pole test 
Motor coordination was measured with the pole 
test: turning time, rotation direction, and the 
downwards walking velocity. No differences were 
detected between the dietary groups concerning 
velocity to descend along the pole (Figure 2F, 
F(1,14)=0.2, p<.909). Mice on Control diet needed 
more time to turn than mice on Fortasyn diet when 
being placed head-upwards on top of the pole (Figure 
2G, F(1,14)=9.0, p<.010). The turning phase requires 
fine-tuned and coordinated movements demanding 
on the potential motor coordination [59]. Notably, 
mice fed Control diet tended to turn more frequently 
to the right to fully turn head-down than mice fed 
Fortasyn diet indicating reduced laterality in the 
Fortasyn fed mice (Figure 2H, F(1,14)=4.3, p<.058). 
Cerebral blood flow (Nijmegen, The 
Netherlands) 
CBF was measured with flow-sensitive 
alternating inversion recovery (FAIR) MRI; from a 
series of echo planar imaging (EPI)-images in three 
different regions of interest (ROI): Cortex, 
hippocampus and thalamus. Each ROI was drawn 
double blind. One representative high-resolution 
voxel-wise analyzed CBF image for each dietary 
group at 7 and 35 after tMCAo is shown (Figure 3B). 
CBF was analyzed for each ROI in the unaffected 
(contralateral/ left) and affected (ipsilateral/ right) 
hemisphere separately for each dietary group at 7 and 
35 poststroke (Figure 3A). Furthermore, loss of CBF in 
the affected ROI was calculated as the difference in 
CBF between right and left hemispheric ROI relative 
to left hemispheric ROI (Figure 3C). 
7 days poststroke CBF in the right cortex 
(Control, F(1,12)=46.9, p<.001; Fortasyn, F(1,12)=38.8, 
p<.001), right hippocampus (Control, F(1,12)=148.2, 
p<.001; Fortasyn, F(1,12)=34.6, p<.001), and right 





thalamus (Control, F(1,12)=12.3, p<.005; Fortasyn, 
F(1,12)=60.7, p<.001) were lower than corresponding 
left ROI in mice for both diets. At this time point, mice 
on Fortasyn demonstrated higher CBF in the right 
affected cortex than mice on Control diet (Fortasyn, 
F(1,12)=7.7, p<.017). 
35 days poststroke only mice on Control diet 
demonstrated lower CBF in right cortex (F(1,12)=5.2, 
p<.043), right hippocampus (F(1,12)=9.4, p<.010), and 
in right thalamus (F(1,12)=8.1, p<.015) compared to 
corresponding left ROI. Contrarily, mice on Fortasyn 
showed only a decreased CBF in right thalamus 
compared to left thalamus (F(1,10)=17.3, p<.002). 
Moreover, Fortasyn mice had a higher CBF than 
Control mice in left cortex (F(1,11)=5.4, p<.040), right 
hippocampus (F(1,11)=5.2, p<.045), and also the left 
thalamus (F(1,11)=7.4, p<.020) over time. 
We also investigated CBF over time from 7 days 
to 35 days poststroke. While animals on Control diet 
showed only a decreased CBF in left cortex 
(F(1,12)=17.7, p<.002) and in left hippocampus 
(F(1,12)=3.7, p<.079) over time, animals on Fortasyn 
diet did not show these decreases (left cortex, 
F(1,11)=1.4, p<.256; left hippocampus, F(1,11)=.0, 
p<.886), and had an increased CBF in the right 
hippocampus (F(1,11)=7.6, p<.019) and right thalamus 
(F(1,11)=6.1, p<.032) over time. 
At 7 days poststroke, Fortasyn mice exhibited a 
lower decrease in cortical CBF than Control mice 
(F(1,12)=7.7, p<.017). This beneficial effect was also 
seen at 35 days poststroke in the hippocampus of 
Fortasyn fed mice compared with Control diet fed 
mice (F(1,11)=5.5, p<.040). From 7 to 35 days 
poststroke both dietary groups showed a less 
impaired CBF in cortex (Control, F(1,12)=10.9, p<.007; 
Fortasyn, F(1,11)=5.5, p<.040) and hippocampus 
(Control, F(1,12)=6.7, p<.024; Fortasyn, F(1,11)=10.1, 
p<.009), while this improvement was also revealed in 
the thalamus of Fortasyn mice only (Control, 
F(1,12)=2.4, p<.147; Fortasyn, F(1,11)=7.9, p<.018). 
Diffusion tensor imaging (Nijmegen, The 
Netherlands) 
Quantitative assessment of diffusion tensor 
derived indices (fractional anisotropy, FA, Figure 4B; 
and mean diffusivity, MD, Figure 4C) was performed 
for ROI drawn in white and gray matter regions to 
assess diet and time effects 7 and 35 days poststroke. 
Fractional anisotropy 
Fortasyn mice showed a trend of an increased 
FA in the right Motor Cortex (MC) compared to 
Control (F(1,22)=4.2, p<.053) at 7 and 35 days 
poststroke. Notably, a diet effect was found over time 
in the ROI containing the right Caudate, Putamen and 
Globus Pallidus (Cpu+GP, F(1,22)=3.8, p<.065). More 
specifically, only mice on Fortasyn showed an 
increase in FA in the right Cpu+GP over time 
(F(1,11)=1.2, p<.044), while mice on Control diet did 
not show this increase. 
All mice, showed increased FA over time 
poststroke in the left Corpus Callosum (CC, 
F(1,22)=3.8, p<.065), left Hippocampus (HC, 
F(1,22)=5.6, p<.028), right HC (F(1,22)=9.0, p<.007), 
and left optic tract (F(1,22)=4.1, p<.055). 
7 days poststroke in both dietary groups a lower 
FA was measured in the right caudate CPu+GP 
compared with CPu+GP in the left hemisphere 
(Control, F(1,12)=6.4, p<.027; Fortasyn, F(1,12)=9.1, 
p<.011).  
While Fortasyn mice showed no significant 
decrease of FA in the right ROI compared with the 
corresponding left ROI at 35 days poststroke, Control 
mice showed a lower FA in the right visual cortex 
(VC, F(1,10)=6.5, p<.030) compared to left VC.  
Mean diffusivity 
Again, at 7 and 35 days poststroke Fortasyn mice 
had a lower MD in the right MC than Control mice 
(F(1,22)=4.0, p<.059, trend). Notably, a diet effect was 
found over time in the left Cpu+GP (F(1,22)=3.4, 
p<.078): only mice on Control diet showed a 
non-significant decreased MD in the left Cpu+GP 
over time (F(1,11)=4.2, p<.066). In all mice, MD tended 
to decrease over time in the Fornix (F(1,22)=3.8, 
p<.065). 
While Fortasyn mice showed no MD increase in 
the right hemisphere ROI compared with the 
corresponding left hemisphere ROI at 35 days 
poststroke, Control mice showed a higher MD in the 
right Cpu+GP (F(1,10)=9.9, p<.030) compared to left 
Cpu+GP.  
Resting state fMRI (Nijmegen, The 
Netherlands) 
To compare functional connectivity (FC) patterns 
at 7 and 35 days poststroke and on different diets, 
rsfMRI data were statistically analyzed based on total 
(Supplemental figure 2A-C) and partial correlation 
(Figure 5A-C) in twelve ROI including: left and right 
dorsal hippocampus (DH), left and right ventral 
hippocampus (VH), left and right auditory cortex 
(AU), left and right motor cortex (M1), left and right 
somatosensory cortex (S1), and left and right visual 
cortex (V1). 
Total correlation analyses  
With total correlations no significant diet effects 
nor time effects (Supplemental figure 2B,C) were 
measured. 






Fig. 4. Quantitatively assessed diffusion tensor derived indices at 7 + 35 days poststroke in mice fed Fortasyn or Control diet. Fractional 
anisotropy (FA) and mean diffusivity (MD) were measured for ROI drawn in white and gray matter regions (AUC=auditory cortex, CC=corpus 
callosum, F=fornix, HC=hippocampus, MC=motor cortex, OT=optic tract, SSC=somatosensory cortex, VC=visual cortex, Cpu+GP= caudate 
putamen+globus pallidus). Values represent mean±SD. (A) Representative high-resolution set of three (Bregma: 0.38, -1.34, -2.92) FA images is shown for each 
dietary group 7 and 35 days poststroke. (B) Fortasyn mice showed a higher FA in the right MC than Control mice (p<.053) 7 and 35 days poststroke. Only mice on 
Fortasyn showed an increased FA in right Cpu+GP over time (p<.044). In all mice, FA increased from day 7 to day 35 poststroke in left CC (p<.065), left HC (p<.028), 
right HC (p<.007), and left OT (p<.055). Both dietary groups demonstrated a lower FA in right Cpu+GP compared to left Cpu+GP (Control, p<.027; Fortasyn, 
p<.011) 7 days poststroke. Control mice showed a lower FA in right VC (p<.030) compared to left VC. (C) Fortasyn mice showed a lower MD in the right MC than 
Control mice overtime (p<.059, trend). Only Control fed mice showed a non-significant decrease in MD in left Cpu+GP over time (p<.066). In all mice, MD seemed 
to decrease again from day 7 to day 35 poststroke in the F (p<.065). Only Control mice showed a higher MD in right Cpu+GP (p<.030) than in left Cpu+GP. 
 
Partial correlation analyses  
Partial correlation analysis accentuates the direct 
connectivity between two ROI, while regressing the 
temporal BOLD signal from all other ROI. For the 
partial correlations we found significant diet effects at 
7 and 35 days poststroke (Figure 5B).  
At 7 days after tMCAo Fortasyn mice showed a 
decreased FC between left and right DH (F(1,8)=11.2, 
p<.011), and between right DH and left AU 
(F(1,8)=5.4, p<.050). In contrast, already at 7 days 
poststroke Fortasyn exhibited an increased FC 
between right AU and right V1 (F(1,8)=6.2, p<.038).  
At 35 days poststroke Fortasyn mice showed 
only a decreased FC between left DH and left V1 
(F(1,8)=5.7, p<.044), while FC between right VH and 
left AU (F(1,8)=5.5, p<.048), and between right AU 
and left M1 (F(1,8)=6.8, p<.032) was increased in mice 
fed the Fortasyn diet. 
For the partial correlations we found significant 
time effects in mice on both diets (Figure 5C). Main 
findings were less negative effects over time in 
animals fed Fortasyn than animals fed the Control 
diet. Furthermore, a beneficial effect on FC between 
left and right M1 was revealed only in Fortasyn mice. 
On Control diet, FC was lowered between left 
DH and right S1 (F(1,8)=11.6, p<.010), between left VH 
and right AU (F(1,8)=6.2, p<.038), between right VH 
and left AU (F(1,8)=22.9, p<.002), and between right 





AU and left M1 (F(1,8)=6.5, p<.035), while FC was 
heightened between right DH and left VH (F(1,8)=5.9, 
p<.041), between right AU and left DH (F(1,8)=13.9, 
p<.006), and between left V1 and left M1 (F(1,8)=5.9, 
p<.041). 
On Fortasyn diet, FC was decreased only 
between left DH to left VH (F(1,8)=5.3, p<.050) and 
right AU to left V1 (F(1,8)=9.1, p<.017). Notably, mice 
on Fortasyn had a higher FC between left and right 
M1 over time (F(1,8)=6.8, p<.032). 
PET results (Münster, Germany) 
N=24 mice underwent tMCAo surgery and were 
intra-individually followed 7d, 14 d, and 35 d 
poststroke by PET using the TSPO ligand 
[18F]DPA-714. [18F]DPA-714 signal appeared within 
and around the infarct as determined by T2w-MRI 
(Figure 6A). In accordance, immunohistochemical data 
showed good spatial agreement as well as reduced 
TSPO levels in the Fortasyn group (Figure 6B). Double 
staining immunohistochemistry for TSPO and GFAP 
indicates astrocytes as source of TSPO at late time 
points after stroke (Figure 6C). 
Investigation of diet effects over time revealed 
that [18F]DPA-714 mean uptake ratios (Figure 6D) 
were significantly reduced from 7 to 35 d poststroke 
in the Fortasyn group (Lmean/Cmean: 1.43+/-0.16; 
n=5) when compared to Control animals 
(Lmean/Cmean: 1.58+/-0.16; n=5; F(1,8)=7.1, p<.029). 
Similarly, comparison of the maximum [18F]DPA-714 
radio uptake ratios (Figure 6E) highlighted reduced 
[18F]DPA-714 uptake in the Fortasyn diet group from 
7 to 35 d poststroke (Lmax/Cmean: 1.57+/-0.23; n=5) 
as compared to the Control diet group (Lmax/Cmean: 
2.21+/-0.20; n=5; (F(1,8)=9.4, p<.016). 
Immunohistochemical procedures  
In the supplemental material (supplemental 
figures 3-7) for each immunohistochemical staining a 
set of photos is given showing photos of each animal 
group in each ROI. 
GLUT-1 staining (Nijmegen, The Netherlands) 
All brains were processed for 
immunohistochemical staining with GLUT-1 
antibody (glucose transporter-1). In order to reveal 
the changes in total GLUT-1 amount as well as in 
capillary density, we measured relative GLUT-1+ area 
and counted manually the amount of GLUT-1+ blood 
vessels in the cortex, hippocampus, and thalamus 
(Figure 7A-C).   
No diet effects were found for total GLUT-1 
amount in the cortex, hippocampus, and thalamus 
(Figure 7B). Notably, Fortasyn mice had more GLUT-1 
positive blood vessels in the cortex than Control mice 
(Figure 7C, F(1,13)=5.8, p<.024), especially in the right 




Fig. 5. Resting-state functional connectivity (FC) based on partial correlation analyses (A) in the brains of mice fed Fortasyn or Control diet 7 
and 35 days poststroke. FC was measured between 12 ROI: dorsal hippocampus (DH), ventral hippocampus (VH), auditory cortex (AU), 
motor cortex (M1), somatosensory cortex (S1), and visual cortex (V1). (B) 7 days poststroke Fortasyn mice showed decreased FC between DH and right 
DH p<.011), and between right DH and left AU (p<.050). Fortasyn mice exhibited an increased FC between right AU and right V1 (p<.038) 7 days poststroke. At 35 
days after tMCAo Fortasyn mice showed decreased FC between left DH and left V1 (p<.044), while FC between right VH and left AU (p<.048), and between right 
AU and left M1 (p<.032) was increased in Fortasyn mice. (C) On Control diet, FC was lowered over time between several ROI, e.g. left DH and right S1 (p<.010), 
while FC was increased between left V1 and left M1 (p<.041). On Fortasyn diet, FC was decreased between left DH to left VH (p<.050) and right AU to left V1 
(p<.017). Fortasyn fed mice had a higher FC between left and right M1 over time (p<.032). 






Fig. 6. Positron Emission Tomography (PET) of microglial activation. (A) Representative intra-individual MR images and fusion images over time with PET 
of mice fed with the Control diet (left) versus mice fed with the Fortasyn diet (right). Fortasyn fed mice showed a reduced uptake of [18F]DPA-714 in the infarction 
after 35 days. (B) Comparison of [18F]DPA-714 with TSPO immunohistochemistry reveals reduced TSPO staining in Fortasyn animals (Scale bar: 1000µm and 50µm). 
(C) Irrespective of the dietary intervention, TSPO (red) is also expressed by astrocytes (green) 35d after tMCAo (Scale bar: 100µm. (D) Values represent mean+SD. 
[18F]DPA-714 mean uptake ratios were significantly reduced from 7 to 35 d after tMCAo in the Fortasyn group when compared to Control animals (p<.029). (E) 
Comparison of the max [18F]DPA-714 radio uptake ratios highlighted reduced [18F]DPA-714 uptake in the Fortasyn diet group from 7 to 35 d (p<.016). 
 
IBA-1 staining (Nijmegen, The Netherlands) 
The brains of all mice were 
immunohistochemically stained with an antibody 
against ionized calcium-binding adapter molecule 1 
(IBA-1, Figure 7D). IBA-1 is expressed by microglia, 
but also by phagocytes in general (monocytes and 
macrophages). We measured relative IBA-1+ area and 
the amount of IBA-1+ cells in the cortex, 
hippocampus, and thalamus (Figure 7D-F).  
Compared to the left thalamus, the right 
thalamus revealed an increased relative IBA-1+ area 
(Figure 7E, F(1,26)=12.2, p<.002) and also an increased 
amount of IBA-1+ cells (Figure 7F, F(1,26)=21.8, 
p<.001) in mice on both diets. While mice on Fortasyn 
seemed to have a decreased relative IBA-1+ area in 
the cortex (F(1,28)=4.0, p<.057) and the hippocampus 
(F(1,24)=4.1, p<.054) compared with mice on Control 
diet, a non-significant increased relative IBA-1+ area 





was seen in the thalamus of Fortasyn mice 
(F(1,26)=3.5, p<.074). In addition, mice on Control diet 
had more IBA-1+ cells in their right hippocampus 
than mice on Fortasyn (Figure 7F, F(1,12)=5.5, p<.037), 
and also all mice on Fortasyn showed less IBA1+ cells 
in the total hippocampus than mice on Control diet. 
(Figure 7F, F(1,24)=4.8, p<.039).  
DCX staining (Nijmegen, The Netherlands) 
Immature neurons were visualized in all mice 
with a polyclonal antibody against doublecortin 
(DCX). As a measure for neurogenesis, DCX+ cells 
were counted in the subgranular zone of the 
hippocampus (Figure 7G+H) and DCX+ area was 
measured also in the subventricular zone (SVZ, Figure 
7I+J). 
No diet effects were found in the hippocampus. 
In the right SVZ Fortasyn fed mice had more DCX+ 
area than in their left SVZ (Figure 7J, F(1,12)=4.9, 
p<.047), and than Control fed mice in the same ROI 
(Figure 7J, F(1,12)=5.4, p<.039).  
 
 
Fig. 7. Immunohistochemical stainings for glucose transporter-1 (GLUT-1, A-C), ionized calcium-binding adapter molecule 1 (IBA-1, D-F), 
doublecortin (DCX, G-J), synaptophysin (SYN, K-L) and Postsynaptic Density-95 Protein (PSD-95, N-P) on brains of Fortasyn and Control fed 
mice 35 days after tMCAo. Values represent mean±SD. (C) Fortasyn mice had more GLUT-1+blood vessels in the cortex than Control fed mice (p<.024), 
especially in the right cortex (p<.034) indicating a higher vascular density. (E) Mice on Fortasyn seemed to have a decreased relative IBA-1+ in cortex (p<.057) and 
hippocampus (p<.054) compared to Control fed mice. (E+F) The right thalamus showed a larger IBA-1+ area (p<.002) and more IBA-1+ cells (p<.001) than the left 
thalamus in mice on both diets. (F) Control fed mice had more IBA-1+ cells in the right hippocampus than Fortasyn fed mice (p<.037), whereas Fortasyn mice showed 
less IBA1+ cells in total hippocampus compared to Control (p<.039). (G-J) DCX+ cells were counted in the subgranular zone of the hippocampus (G+H) and in the 
subventricular zone (SVZ) (I+J). (J) Fortasyn fed mice had more DCX+ area in the right SVZ than in left SVZ (p<.047), and in the same ROI of Control fed mice 
(p<.039). (M) All mice showed a decreased relative SYN+ area in the right caudate putamen (Cpu, p<.006) compared to the left Cpu. (O+P) All mice had a lowered 
PSD-95+ area in the right cortex (p<.003) and in the right Cpu (p<.001) compared to the corresponding left ROI. 
 





SYN and PSD-95 staining (Nijmegen, The 
Netherlands) 
The amount of presynaptic boutons was 
visualized with a monoclonal antibody against 
synaptophysin (SYN). Whereas, postsynaptic density 
was stained with a polyclonal antibody against 
postsynaptic density protein 95 (PSD-95) reflecting 
synaptic function. Both pre- (Figure 7K-M) and 
postsynaptic (Figure 7N-P) density were measured in 
the cortex and caudate putamen (Cpu). 
No diet effects were found in the cortex and Cpu 
for both the relative SYN+ and PSD-95+ area. All mice 
showed a decreased relative SYN+ area in the right 
Cpu (Figure 7M, F(1,25)=9.2, p<.006) compared to 
corresponding left ROI. 
All mice had a lowered PSD-95+ area in the right 
cortex (Figure 7O, F(1,26)=11.3, p<.003) and also in the 
right Cpu (Figure 7P, F(1,24)=35.5, p<.001) compared 
to corresponding left ROI. 
TSPO immunohistochemistry (Münster, Germany) 
Spatial comparison of [18F]DPA-714 with 
immunohistochemistry for TSPO at 35 days after 
stroke revealed good spatial agreement. However, 
reduced TSPO immunohistochemistry was observed 
in Fortasyn treated animals (Figure 6B). Interestingly, 
35 d after stroke astrocytes (GFAP) also expressed 
TSPO. (Figure 6C). 
Discussion  
The present data show that the specific nutrient 
combination Fortasyn may enhance recovery from 
ischemic stroke in mice, as evidenced by improved 
cerebral blood flow, reduced loss of functional 
connectivity, and improved motor performance. 
Relevant processes for recovery after stroke, such as 
neurogenesis, angiogenesis, and neuroinflammation, 
were positively affected by the Fortasyn diet.  
Cerebral hemodynamics 
CBF was increased already at seven and also at 
35 days poststroke in mice on Fortasyn diet. Notably, 
CBF dropped over time in several brain regions in 
Control mice from 7 to 35 days poststroke, while this 
decrease was not seen in Fortasyn mice. These results 
are in accordance with our previous research showing 
that this nutrient combination is able to improve 
cerebral perfusion in mice models of (vascular risk 
factors for) Alzheimer's disease (AD) [35, 36]. In 
addition, improved vascular density due to an 
increased angiogenesis was found in the cortex of 
Fortasyn fed mice. This improved vascular health 
may explain the beneficial effects of Fortasyn on 
cerebral hemodynamics after the ischemic event. 
DTI and rsfMRI 
In the present study we investigated brain 
diffusivity with DTI as an imaging biomarker for 
white and gray matter integrity. FA is a marker of the 
degree of myelination and fiber density of white 
matter (WM), while MD characterizes an inverse 
measure of the membrane density and is sensitive to 
cellularity, edema, and necrosis in grey matter (GM) 
[73-75]. Here, we revealed an impaired WM 
microstructure at seven days poststroke in regions 
containing the Caudate Putamen and Globus Pallidus 
of both dietary groups. Notably, microstructural 
integrity of WM was restored in Fortasyn mice over 
time in affected regions containing Caudate Putamen 
and Globus Pallidus of the affected hemisphere. 
Moreover, at 7 and 35 days poststroke a slight 
beneficial effect on WM microstructure of the right 
Motor cortex was also seen only in Fortasyn mice. 
Also an improved GM microstructure in the right 
Motor cortex of Fortasyn animals at seven and 35 
days, and an impaired GM integrity (an increase in 
MD) in regions containing the right Caudate Putamen 
and Globus Pallidus of only mice on Control diet was 
measured. Thus, Fortasyn may limit the damage to 
existing structures and may also support the 
regeneration of lost connectivity. Comparable results 
were found in other studies showing that 
intracerebral injection of EPA is able to stimulate the 
expression of myelin proteins in rat pup brain [76]. 
Partial correlations of functional connectivity data 
revealed several beneficial diet effects already at 7 and 
also at 35 days poststroke. Fortasyn diet increased FC 
between several brain regions, and over time Fortasyn 
limited loss of FC compared to Control diet. Notably, 
Fortasyn mice showed an improved interhemispheric 
FC between the motor cortices supporting the 
therapeutic value of Fortasyn already after 35 days. 
The importance of dietary composition for developing 
and maintaining distributed brain systems was 
shown in another preclinical rsfMRI study showing 
that n3-LCPUFA are crucial for functional 
connectivity and large-scale system organization in 
rhesus macaque brains [77]. Additionally, in a 
24-week randomized, controlled, double-blind, 
parallel-group, multi-country study de Waal et al. 
explored the effect of a nutritional intervention with 
Fortasyn on brain activity-based networks. They 
showed that the nutritional intervention preserved 
the organization of brain networks in patients with 
mild AD within 24 weeks potentially via 
counteracting the progressive network disruption 
over time in AD [78]. In addition, in a recent study 
Fortasyn ameliorated deficits in FC in a mouse model 
for asymptomatic AD [35]. Notably, in a longitudinal 
observational clinical study acquiring rsfMRI data 4 





times over a period of 6 months Park et al. 
demonstrated that FC of the ipsilesional M1 with the 
contralesional thalamus, supplementary motor area, 
and middle frontal gyrus at onset was positively 
correlated with motor recovery at 6 months after 
stroke [79].  
Molecular alterations 
The combination of phosphatide precursors like 
n3-LCPUFA, uridine, and choline, has proven to 
synergistically increase the synthesis of synaptic 
proteins and phospholipids in the brain [30-32]. In our 
study, a decreased amount of pre- and postsynaptic 
markers in the ipsilateral cortex and caudate putamen 
was observed indicating a significant negative effect 
of experimental stroke on synthesis and maintenance 
of synaptic proteins. Kawakita et al. demonstrated 
that DHA effectively promotes neurogenesis both in 
vitro and in vivo [80]. Notably, even in an experimental 
murine stroke model our specific nutrient 
combination was able to increase neurogenesis. Here, 
we measured via DCX a significant enhanced 
neurogenesis in the right (affected) border zones of 
the lateral ventricle in Fortasyn fed animals indicating 
accelerated (neuronal) membrane synthesis.  
Neuroinflammation 
[18F]DPA-714 is a ligand for the 18 kDa 
translocatorprotein (TSPO), which is highly expressed 
by microglial cells upon neuroinflammatory stimuli. 
Previous studies have shown that the majority of PET 
signal is due to increased expression of TSPO by 
microglia [46, 81]. Therefore, [18F]DPA-714 has now 
already been used in a variety of clinical studies in 
neurological diseases [82]. However, due to the lack of 
specific markers and antibodies reliably 
distinguishing microglia and macrophages it cannot 
be excluded that macrophages contribute to the 
signal. We and others have shown that under rather 
chronic conditions astrocytes faintly express TSPO 
(see Fig. 7C and [83]), whereas at early-intermediate 
time points (24h-14 days) after stroke astrocytes seem 
not play an important role [46]. A decreased 
neuroinflammation/ microglial activation was 
observed with Fortasyn for up to 35 days post stroke 
by PET imaging. The beneficial function of Fortasyn 
was likely mediated by a reduction of IBA-1 positive 
cells. IBA-1, which is expressed in activated microglia 
and macrophages, was reduced at 35 days post stroke 
in the cortex and the hippocampus of Fortasyn mice. 
Notably, Harvey et al. could not show an effect of 
single administration of DHA on IBA-1 at three, 7, 
and 21 days after TBI on neuroinflammation in 
post-traumatic brain injury (TBI) in Sprague Dawley 
rats, indicating that a combination of factors may 
enhance diet function. However, they also showed 
that DHA may be able to facilitate the polarization of 
microglia or macrophages into an anti-inflammatory 
and reparative microglia phenotype [84]. The reduced 
neuroinflammatory response might also explain the 
beneficial effects on functional and structural 
connectivity. Several recent studies indicated that 
microglia are crucially involved in processes of 
synaptic remodeling and plasticity in the healthy 
brain [85-87]. In future preclinical stroke research the 
impact of Fortasyn on glial cells needs to be studied, 
since DHA as single component by itself is already 
able to modulate glial cell activity by regulating gene 
expression and release of inflammatory mediators, as 
well as serving as substrate for specialized 
pro-resolving mediators [88-90]. 
Motor function 
Fortasyn mice tended to have more grip strength 
with all four limbs compared to control mice. This 
effect could partly be due to the beneficial effects of 
the Fortasyn diet on cerebral regions involved in 
motor functions. During the turning phase of the pole 
test set of fine-tuned and coordinated movements are 
required [59]. In the current study mice on Control 
diet needed more time to turn on the pole than mice 
on Fortasyn diet. In addition, Control mice showed a 
lateral bias at 15 days poststroke which was not 
present in Fortasyn mice. These latter results are in 
accordance to the recent study of Bourourou et al.. 
Here, the dietary supplementation with the omega-3 
precursor, alpha-linolenic acid, was more effective in 
improving motor coordination in a mouse model of 
ischemic stroke than intravenous treatment [91]. 
Notably, at 23 days poststroke all Fortasyn mice 
walked more often than the Control mice and also 
more often than at three days poststroke indicating an 
improved locomotion. These latter results are in line 
with other studies demonstrating that DHA treatment 
has beneficial effects on locomotor activity [9, 35]. 
While Cao et al. focused only on the preventive effect 
of DHA treatment and Hong et al. on the acute phase 
after stroke, in our study we now finally get one step 
further towards effective acute treatment for recovery 
after stroke which is still lacking for many stroke 
patients. The pole and grip test were not performed at 
multiple time points after tMCAo like the Rotarod or 
open field. Future studies should repeat these motor 
tests at multiple time points to obtain additional 
indications of the long-term effects of Fortasyn on 
motor performance at later time points poststroke. 
Particularly, rodents are well known to be able to 
compensate functional differences rather than 
presenting true recovery after an experimental stroke 
[92]. Notably, an example of functional compensation 





in our study is the improved functional connectivity 
over time in our control mice. Here, control mice also 
showed an improved functional connectivity between 
several brain regions, being not present in animals on 
Fortasyn diet. Here, we were able to demonstrate 
beneficial dietary effects already at 7 and also at 35 
days post experimental stroke. Future studies should 
also focus on more severe stroke models to study the 
beneficial effects of multi-nutrient interventions. 
We showed improvement of long-term outcome 
using a specific combination of nutrients. Notably, in 
the current experiments no effect on body weight was 
detected, but all Fortasyn mice seemed to have a 
higher food intake during all 35 days after an 
experimental stroke.  
We did not find diet effects on cognition in the 
novel object recognition test (ORT) measured from 22 
to 24 days poststroke. This absent effect is in line with 
previous research of Wang et al. who demonstrated a 
significantly reduced preference at 7 and 14 days 
following stroke, but normal values between 21 and 
28 days post-stroke, within the ORT [93]. Therefore in 
future research, the ORT should be performed earlier 
after the induction of the experimental stroke to reveal 
subtle dietary effects.  
Summary and conclusions  
This international, multicenter preclinical study 
was exerted according to ARRIVE and STAIR 
guidelines [41-44] revealing that multimodal 
neuroimaging combined with behavioral analysis is 
an excellent approach to assess brain and motor 
function recovery after stroke. In addition, this 
experimental setup shows the beneficial effects of an 
academic-industry collaboration and an 
industry-relevant translational research covering 
many aspects and complexities of a multicenter 
multimodal paradigm [71, 72]. In conclusion, our data 
indicate that a post-stroke intervention with the 
specific nutrient combination of Fortasyn is able to 
support recovery after ischemic stroke, by improving 
cerebral circulation due to an improved 
vascularization and increased angiogenesis, 
protecting white and gray matter integrity, restoring 
functional connectivity, increasing neurogenesis, 
decreasing the neuroinflammatory response, and 
improving motor skills and muscle strength. No 
therapeutic intervention is available for stroke yet, but 
the broad range of structural and functional 
therapeutic benefits observed in the present study 
indicates clear therapeutic potential of the Fortasyn 
nutrient combination to support functional recovery 
after ischemic stroke. This recent study investigating a 
specific dietary approach which has been tested in 
several mouse models of (risk factors) AD, is the first 
step in the development of tailor-based dietary 
treatments against stroke. Increased adherence to a 
Mediterranean-style diet lowers the risk of ischemic 
stroke [14], and future studies should therefore start 
to focus on optimization of multicomponent 
combinations targeting dietary components of the 
Mediterranean diet to improve clinical outcome after 
a stroke.  






3-yl)acetamide; BW: Body Weight; DCX: 
Doublecortin; EPI: Echo Planar Imaging; FA: 
Fractional Anisotropy; FAIR: Flow-Sensitive 
Alternating Inversion Recovery; FC: Functional 
Connectivity; GLUT-1: Glucose Transporter-1; GM: 
Grey Matter; IBA-1: Ionized Calcium-Binding 
Adapter Molecule 1; MD: Mean Diffusivity; ORT: 
Novel Object Recognition Test; PBS: 
Phosphate-Buffered Saline; pdMCAo: permanent 
distal MCAo; Ppi: Prepulse Inhibition; PSD-95: 
Postsynaptic Density Protein 95; rsfMRI: resting state 
fMRI; SPM: Statistical Parametric Mapping; SYN: 
Synaptophysin; TBI: Traumatic Brain Injury; TSPO: 
Translocator Protein; VOI: Volume of Interest; WM: 
White Matter. 
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